BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: O’neil B, Ison MG, Hallouin-bernard M, Nilsson AC, Torres A, Wilburn JM, van Duijnhoven W, Van Dromme I, Anderson D, Deleu S, Kosoglou T, Vingerhoets J, Rossenu S, Leopold L. A Phase 2 Study of Pimodivir (JNJ-63623872) in Combination With Oseltamivir in Elderly and Nonelderly Adults Hospitalized With Influenza A Infection: OPAL Study. The Journal of Infectious Diseases 2020. [DOI: 10.1093/infdis/jiaa376] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Kumar D, Ison MG, Mira J, Welte T, Hwan Ha J, Hui DS, Zhong N, Saito T, Katugampola L, Collinson N, Williams S, Wildum S, Ackrill A, Clinch B, Lee N. Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial. The Lancet Infectious Diseases 2022;22:718-30. [DOI: 10.1016/s1473-3099(21)00469-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
2 Nakamura T, Isoda N, Sakoda Y, Harashima H. Strategies for fighting pandemic virus infections: Integration of virology and drug delivery. J Control Release 2022:S0168-3659(22)00068-2. [PMID: 35122872 DOI: 10.1016/j.jconrel.2022.01.046] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
3 Patel MC, Chesnokov A, Jones J, Mishin VP, De La Cruz JA, Nguyen HT, Zanders N, Wentworth DE, Davis TC, Gubareva LV. Susceptibility of widely diverse influenza a viruses to PB2 polymerase inhibitor pimodivir. Antiviral Res 2021;188:105035. [PMID: 33581212 DOI: 10.1016/j.antiviral.2021.105035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]